Tango Therapeutics Finalizes CFO Separation Terms, Accelerates 24 Months of Equity Vesting

summarizeSummary

Tango Therapeutics disclosed the separation agreement for its former CFO, including 12 months of severance and the acceleration of 24 months of equity vesting.

check_boxKey Events · Executive and Board Changes · TNGX

• CFO Separation Agreement Finalized

  Tango Therapeutics entered into a Separation Agreement and Release with former Chief Financial Officer Daniella Beckman on May 7, 2026, following her previously announced departure.

• Significant Equity Vesting Accelerated

  The agreement includes the acceleration of 24 months of vesting for Ms. Beckman's outstanding stock options and restricted stock unit awards.

• Extended Option Exercise Period

  All vested stock options, including those newly accelerated, will remain exercisable until August 31, 2026.

• Severance Package Details

  Ms. Beckman will receive 12 months of severance pay at her current base salary and up to 12 months of COBRA premium reimbursement.

auto_awesomeAnalysis · TNGX · Life Sciences

This 8-K details the separation agreement for former Chief Financial Officer Daniella Beckman, whose departure was previously announced. The agreement includes 12 months of severance pay and COBRA reimbursement. Critically, it accelerates the vesting of her outstanding equity awards that would have vested over an additional 24 months, and extends the exercise period for all vested options until August 31, 2026. While the CFO's departure was known, these specific financial terms, particularly the significant equity acceleration, represent a material cost to the company and could lead to future share sales, potentially adding to market overhang.